Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Popovic

Showing results (41-50 of 303) with videos related to

Pageof 31
Sort By:
Expert Review of Endocrinology & Metabolism|October 26, 2025
Basal insulin in the age of innovation: are diamonds still forever?Theocharis Koufakis, Dimitrios Patoulias, Djordje S Popovic, et al.
Advances in Therapy|April 16, 2026
Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic FibrosisTheodoros Panou, Evanthia Gouveri, Djordje S Popovic, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 4, 2021
New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?Djordje S Popovic, Manfredi Rizzo, Edita Stokic, et al.
Current Vascular Pharmacology|March 2, 2022
Ezetimibe and Insulin ResistanceDjordje S Popovic, Stella Papachristou, Edita Stokic, et al.
Expert Review of Clinical Pharmacology|November 23, 2025
Orforglipron in type 2 diabetes mellitus and obesity: an overviewTheodoros Panou, Evanthia Gouveri, Djordje S Popovic, et al.
Metabolism: Clinical and Experimental|June 1, 2022
COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansongTheocharis Koufakis, Djordje S Popovic, Symeon Metallidis, et al.
Journal of Diabetes|September 9, 2022
The importance of sleep quality, quantity, and chronotype in the management of diabetes: Is it time to wake up?Theocharis Koufakis, Giuseppe Maltese, Djordje S Popovic, et al.
Expert Review of Clinical Pharmacology|September 24, 2024
Amylin analogs for the treatment of obesity without diabetes: present and futureTheodoros Panou, Evanthia Gouveri, Djordje S Popovic, et al.
International Journal of Cardiology|July 7, 2024
SGLT2 inhibitors: A groundbreaking class of cardiovascular drugs, but who benefits most?Theocharis Koufakis, Djordje S Popovic, Giuseppe Maltese, et al.
Expert Review of Clinical Pharmacology|June 4, 2025
COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetesDjordje S Popovic, Dimitrios Patoulias, Theocharis Koufakis, et al.
Pageof 31

Showing results (41-50 of 303) with videos related to

Sort By:
Pageof 31
Expert Review of Endocrinology & Metabolism|October 26, 2025
Basal insulin in the age of innovation: are diamonds still forever?Theocharis Koufakis, Dimitrios Patoulias, Djordje S Popovic, et al.
Advances in Therapy|April 16, 2026
Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic FibrosisTheodoros Panou, Evanthia Gouveri, Djordje S Popovic, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 4, 2021
New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?Djordje S Popovic, Manfredi Rizzo, Edita Stokic, et al.
Current Vascular Pharmacology|March 2, 2022
Ezetimibe and Insulin ResistanceDjordje S Popovic, Stella Papachristou, Edita Stokic, et al.
Expert Review of Clinical Pharmacology|November 23, 2025
Orforglipron in type 2 diabetes mellitus and obesity: an overviewTheodoros Panou, Evanthia Gouveri, Djordje S Popovic, et al.
Metabolism: Clinical and Experimental|June 1, 2022
COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansongTheocharis Koufakis, Djordje S Popovic, Symeon Metallidis, et al.
Journal of Diabetes|September 9, 2022
The importance of sleep quality, quantity, and chronotype in the management of diabetes: Is it time to wake up?Theocharis Koufakis, Giuseppe Maltese, Djordje S Popovic, et al.
Expert Review of Clinical Pharmacology|September 24, 2024
Amylin analogs for the treatment of obesity without diabetes: present and futureTheodoros Panou, Evanthia Gouveri, Djordje S Popovic, et al.
International Journal of Cardiology|July 7, 2024
SGLT2 inhibitors: A groundbreaking class of cardiovascular drugs, but who benefits most?Theocharis Koufakis, Djordje S Popovic, Giuseppe Maltese, et al.
Expert Review of Clinical Pharmacology|June 4, 2025
COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetesDjordje S Popovic, Dimitrios Patoulias, Theocharis Koufakis, et al.
Pageof 31